论文部分内容阅读
目的探讨血小板抗体检测技术应用于肿瘤化疗患者血小板输注的疗效观察。方法取63例输注机采血小板无效症的肿瘤化疗患者,采用血小板抗体检测技术筛查血小板抗体,对抗体阳性患者进行血小板交叉配型,选择配合性血小板进行输注。结果筛查结果 63例患者中抗体阳性率为50.8%(免疫因素32例),而抗体阴性率达49.2%(非免疫因素31例)。32例抗体阳性患者输入配合性血小板后输注有效者27例(有效率达84.4%)另有5名患者出现输入血小板存活期减短情况,血小板输注依然无效。结论血小板交叉配型并不能完全避免或逆转化疗患者血小板无效症的发生,因为化疗药物不仅对骨髓有非常强抑制作用,导致血小板减少,同时对输入性血小板有直接的破坏作用,导致血小板输注无效症的增加。
Objective To investigate the therapeutic effect of platelet antibody detection on platelet transfusion in patients with tumor chemotherapy. Methods Totally 63 cases of patients with chemotherapy-induced thrombocytopenic purpura were enrolled. Platelet antibodies were screened by platelet antibody test, and platelet cross-matching was performed on antibody-positive patients. Results Screening results The positive rate of antibody in 63 patients was 50.8% (32 immune factors), while the antibody negative rate was 49.2% (31 non-immune factors). In the 32 patients with positive antibody, 27 patients with effective transfusion after the combination of platelets (effective rate 84.4%) and 5 patients with shortening of platelet transfusion life, platelet transfusion was still ineffective. Conclusion Platelet crossmatch does not completely avoid or reverse the platelet failure in chemotherapy patients. Chemotherapy drugs not only have a strong inhibitory effect on bone marrow, but also cause thrombocytopenia. At the same time, it has a direct destroying effect on ITP, leading to platelet transfusion Invalid increase.